H.C. Wainwright reiterates Novavax stock rating on vaccine study By Investing.com

H.C. Wainwright reiterated a Buy on Novavax and raised its price target to $16 from $11, implying about 84% upside from the current $8.67 share price. The call follows positive Phase 4 COMPARE study results for Sanofi’s Nuvaxovid, which showed lower systemic and local reactogenicity than Moderna’s mNEXSPIKE. Novavax also reported Q4 2025 EPS of $0.11 versus -$0.49 expected and revenue of $147 million, helping support a constructive near-term outlook despite ongoing activist pressure from Shah Capital.

Analysis

The market is likely underestimating how much this partnership shifts NVAX from a single-product vaccine story toward a capital-light platform royalty model. That matters because the equity should re-rate on a lower-risk cash flow profile, not just on near-term vaccine demand; if investors believe management can repeatedly monetize external R&D and manufacturing leverage, the multiple can expand faster than the top line.

The more interesting second-order effect is competitive pressure on the mRNA franchise, especially MRNA and to a lesser extent PFE. Safety/reactogenicity positioning is becoming a procurement lever for institutional buyers, and even a modest share shift in boosters could force rivals into heavier pricing concessions or marketing spend to defend share. That compresses industry economics without needing a dramatic volume loss.

For SNY, this is a validation event for the partnership model and may support further upstream asset selection around immunology and vaccines. The hidden risk is that the market extrapolates a durable moat from a data point that may not translate cleanly across populations, variants, or future seasons; if incremental uptake stalls, the story reverts to episodic event-driven trading rather than a sustained rerating.

The consensus may be too focused on the upside narrative from better study data and insufficiently focused on governance and financing overhangs. Activism can be catalytic if it forces disciplined capital allocation, but it can also surface internal friction just as the company needs execution stability to monetize this window. Expect the stock to be more sensitive to partnership milestones and board actions over the next 1-3 months than to broader vaccine demand trends.

Key Decisions for Investors

• Long NVAX vs short MRNA into the next 4-8 weeks: thesis is relative rerating from capital-light optionality and safer-product positioning; target 15-25% spread capture, stop if NVAX fails to hold post-news gains or MRNA secures a new share-defending catalyst.
• Add to NVAX on pullbacks over the next 1-2 weeks, but size as a catalyst trade rather than a core holding: upside is a move toward the high end of analyst targets if partnership monetization continues; downside is sharp if governance noise or execution doubts resurface.
• Short MRNA on strength for a 1-3 month horizon if booster-share commentary turns defensive: risk/reward favors downside because pricing power can erode faster than headline volumes, especially if institutional buyers emphasize tolerability.
• Avoid chasing SNY long purely on the article; use it as a quality-benefit signal only if there is a broader vaccine franchise read-through. The incremental upside is likely modest relative to SNY’s scale, so reward/risk is better in the smaller-cap dislocation.
• For more aggressive positioning, buy near-dated NVAX call spreads into the next partnership/board catalyst window: defined-risk exposure to a rerating, with the main risk being that the market treats this as another transient headline rather than a durable strategic shift.